Sign inJoin waitlistJoin the waitlist

Mohamed Abdelbaki

Director, Neuro Oncology Program Director, Neuro-Oncology Fellowship · Washington University/B-JH/SLCH Consortium

Credentials: · · ·

History

Neuro Oncology, Neuro-Oncology Fellowship · Washington University/B-JH/SLCH Consortium
Present
Pediatric Brain Tumor Program · Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Pediatric Hematology/Oncology
Washington University/B-JH/SLCH Consortium
2011–2014
Pediatrics
2008–2011
Cairo University Kasr Alainy Faculty of Medicine
1998–2002

Research

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
New England Journal of Medicine · 2021 · 288 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine · 2024 · 168 citations
Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma
Cytotherapy · 2017 · 118 citations

JF
Jonathan Finlay
17 papers
Mohammad Abu-Arja
9 papers · 8 as a resident
Girish Dhall
8 papers
MS
Margaret Shatara
8 papers
Sabine Mueller
8 papers
Ashley Margol
7 papers
Daniel Boue
7 papers
Amar Gajjar
6 papers
LH
Lindsey Hoffman
6 papers
Sarah Leary
6 papers
Andrew Cluster
5 papers
GM
George Michaiel
5 papers

Clinical trials

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Principal investigator · Recruiting · Phase 2
Children's Oncology Group
2024–2033
Digoxin Medulloblastoma Study
Site PI · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2026–2027
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Site PI · Recruiting · Phase 2
University of California, San Francisco
2025–2032
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Site PI · Recruiting · Phase 2
Sabine Mueller, MD, PhD
2022–2028